Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS

CONTEXT: Metabolic dysfunction–associated fatty liver disease (MAFLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM); however, there is still no approved pharmacological treatment. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been suggested to beneficially modify...

Descripción completa

Detalles Bibliográficos
Autores principales: Borisov, Angel N, Kutz, Alexander, Christ, Emanuel R, Heim, Markus H, Ebrahimi, Fahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584001/
https://www.ncbi.nlm.nih.gov/pubmed/37149821
http://dx.doi.org/10.1210/clinem/dgad249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584001/
https://www.ncbi.nlm.nih.gov/pubmed/37149821
http://dx.doi.org/10.1210/clinem/dgad249

Ejemplares similares